Massachusetts insurance commission ends GLP-1 coverage for weight management alone
Massachusetts' Group Insurance Commission voted 10-7 to end GLP-1 coverage for weight management alone, a change that affects state and many municipal employees.
The Massachusetts Group Insurance Commission voted 10-7 in February 2026 to stop covering GLP-1 medications when they are prescribed solely for weight management [1]. The commission designs health plans for state employees and many municipal employees, and the vote followed a request from Governor Maura Healey to cut more than $100 million from workers' health care costs [1].
Healey called on the GIC in January to redesign those plans and aim for more than $100 million in savings [1]. The commission responded with proposals that raised deductibles and copays and eliminated GLP-1 coverage unless the drugs were prescribed for more than weight management [1].
Union members, including the Massachusetts Teachers Association, organized against the cost shifts. Healey then asked the GIC not to put the new plan design changes in place, which the MTA described as a major victory for workers, retirees and their families; the proposed shifts would have led most plan subscribers to pay hundreds of dollars more, and possibly thousands more, each year for health care [1]. Healey continued to advocate for ending GLP-1 coverage for weight loss [1].
The coverage change leaves the drugs covered when they are prescribed for another purpose. Dean Robinson, the MTA's representative on the GIC and a member of the Massachusetts Society of Professors at UMass Amherst, argued before the vote that separating obesity from the illnesses it causes does not make sense. "When a doctor prescribes a GLP-1 for weight loss in these patients, they're treating the root cause of the heart disease and hypertension we're already paying to manage," he said. "The proposal draws a billing line, not a medical one. Same patient, same heart disease, same drug — covered with a diabetes code, not covered without one." [1]
Union response
MTA members are continuing to campaign to restore full coverage. MTA President Max Page said Healey's Health Care Affordability Work Group should partner with public sector unions, which he said have negotiating expertise and market leverage to keep GLP-1 coverage affordable without driving premiums higher [1]. Vice President Deb McCarthy said, "We understand the budgetary pressures created by coverage of GLP-1 medications. But we need time to develop a strategy for making access to GLP-1 drugs affordable." [1]
Rosa Taormina, president of the union representing administrators at state universities, credited GLP-1 medications with improving her health and said the state "has never singled out people with cancer or families seeking IVF treatment to close a budget gap." [1]
Sam Sharp, a member of the University Staff Association at UMass Amherst, said losing coverage would mean leaving state employment. "After losing well over 100 pounds with the aid of GLP-1 medications, the state of Massachusetts wants to take away what is a lifetime drug and condemn me back to immobility and isolation," Sharp said. "If GLP-1s are taken away from state employees, I will have to find a new job." [1]
Bill Forster, a retired Cambridge Education Association member, maintains an email list of 480 members and their spouses and encouraged them to contact the governor and the GIC chair [1].
Why it matters for patients
People covered by GIC plans who take semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) for weight loss alone would no longer have those prescriptions covered, while someone with a diagnosis such as diabetes would keep coverage for the same drug [1]. Taormina said public employees whose wages have not kept pace with housing, groceries and insurance premiums have no realistic way to pay out of pocket for medications that cost thousands of dollars each year [1].
It has not been reported how many GIC members currently use GLP-1 medications for weight management only, when the change takes effect, or how much the commission expects to save from it.
What happens next
The MTA says it will keep organizing to restore full coverage for GLP-1 drugs [1]. McCarthy said the union needs time to develop a strategy for making access to the drugs affordable [1]. No date has been reported for further GIC votes, legislation or negotiations.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.